ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
HighCape Capital Acquisition Corporation

HighCape Capital Acquisition Corporation (CAPA)

10.68
0.00
(0.00%)
Closed December 04 4:00PM
0.00
0.00
(0.00%)

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

CAPA News

Official News Only

CAPA Discussion

View Posts
Quacker Quacker 3 years ago
Where is my mirror Television? :)
👍️0
TallTrader TallTrader 3 years ago
Investor presentation...

https://assets.website-files.com/5e3ba888b619ec2d758ec4cb/602e47a1c5496f3a68af7fed_Quantum-Si%20PIPE%20Master%20Final%20Feb%2018.pdf
👍️0
TallTrader TallTrader 3 years ago
CAPA and Quantum-Si, Pioneer in Chip-Based Proteomics

NEW YORK and GUILFORD, Conn., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Quantum-Si Incorporated (“Quantum-Si”, "QSi" or the "Company"), a pioneer in next generation semiconductor chip-based proteomics, and HighCape Capital Acquisition Corp. (Nasdaq: CAPA) (“HighCape”), a special purpose acquisition company sponsored by HighCape Capital LP, announced today that they have entered into a definitive business combination agreement. Upon completion of the transaction, the combined company's Class A common stock is expected to be traded on The Nasdaq Stock Market (“Nasdaq”) under the symbol "QSI".

Company Overview
Quantum-Si has created the first next-generation protein sequencing platform with the goal of revolutionizing the growing field of proteomics. Our unique semiconductor chip has the power to decode the molecules of life, starting with proteins, and holds the potential to expand the scale of the genomics and proteomics market beyond that of next-generation DNA sequencing.

QSi’s end-to-end solution, including Carbon and Platinum, which is on track to launch commercially in 2022 for research use, has the potential to significantly disrupt an existing addressable $21 billion market of pharmaceutical, academic research and drug discovery. The platform also may enable new diagnostic applications in healthcare.

https://www.globenewswire.com/news-release/2021/02/18/2177804/0/en/Quantum-Si-a-Pioneer-in-Semiconductor-Chip-Based-Proteomics-to-Combine-with-HighCape-Capital-Acquisition-Corp.html
👍️0

Your Recent History

Delayed Upgrade Clock